Brain, Cancer, Cell Motility, Cellular Immunity, Chemokines, Chemotaxis, Imaging, Immunology, Inflammation, Knockout Mice, Macrophage, Microglia, Oncogenes, Organogenesis, Pathology, T Cells, Transgenic Mice, Tumorigenesis, Viruses and Virology
Cancer Biology [CAB], Immunology [IMM]
, Roche Institute of Molecular Biology
MD, U. Federal de Pernambuco
PhD, University of California
Specific Clinical/Research Interest: Chemokines; leukocyte trafficking; angiogenesis; lymphoid development; mouse genetics; cancer inflammation
Postdoctoral Fellows: Lili Chen, Zhengziang He, Vladislav Volarevic
Research Personnel: Research Assistants: Claudia Canasto, Madhura Deshpande, Miranda Mao, Joshua Rivera
Summary of Research Studies:
We use genetic approaches in mice to study the function of cytokines and their receptors in leukocyte trafficking, inflammation and cancer. Recent work in the laboratory focuses:
1) on the role of chemokine-like molecules encoded by herpes and poxviruses in immune evasion and tumorigenesis; and
2) on the role of chemokines in lymphoid organogenesis and autoimmunity.
3) role of microbiome inflammation in cancer.
For more information, please visit the Immunology Institute website.
Lu G, Zhang R, Geng S, Peng L, Jayaraman P, Chen C, Xu F, Yang J, Li Q, Zheng H, Shen K, Wang J, Liu X, Wang W, Zheng Z, Qi CF, Si C, He JC, Liu K, Lira SA, Sikora AG, Li L, Xiong H. Myeloid cell-derived inducible nitric oxide synthase suppresses M1 macrophage polarization. Nature communications 2015; 6.
Brix SR, Stege G, Disteldorf E, Hoxha E, Krebs C, Krohn S, Otto B, Klätschke K, Herden E, Heymann F, Lira SA, Tacke F, Wolf G, Busch M, Jabs WJ, Özcan F, Keller F, Beige J, Wagner K, Helmchen U, Noriega M, Wiech T, Panzer U, Stahl RA. CC Chemokine Ligand 18 in ANCA-Associated Crescentic GN. Journal of the American Society of Nephrology : JASN 2015 Mar;.
Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ, Shih A, Simko SJ, Abhyankar H, Chakraborty R, Leboeuf M, Beltrão M, Lira SA, Heym KM, Clausen BE, Bigley V, Collin M, Manz MG, McClain K, Merad M, Allen CE. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. The Journal of experimental medicine 2015 Feb; 212(2).
Chen L, He Z, Slinger E, Bongers G, Lapenda TL, Pacer ME, Jiao J, Beltrao MF, Soto AJ, Harpaz N, Gordon RE, Ochando JC, Oukka M, Iuga AC, Chensue SW, Blander JM, Furtado GC, Lira SA. IL-23 activates innate lymphoid cells to promote neonatal intestinal pathology. Mucosal immunology 2015 Mar; 8(2).
Disteldorf EM, Krebs CF, Paust HJ, Turner JE, Nouailles G, Tittel A, Meyer-Schwesinger C, Stege G, Brix S, Velden J, Wiech T, Helmchen U, Steinmetz OM, Peters A, Bennstein SB, Kaffke A, Llanto C, Lira SA, Mittrücker HW, Stahl RA, Kurts C, Kaufmann SH, Panzer U. CXCL5 drives neutrophil recruitment in TH17-mediated GN. Journal of the American Society of Nephrology : JASN 2015 Jan; 26(1).
Noriega VM, Gardner TJ, Redmann V, Bongers G, Lira SA, Tortorella D. Human cytomegalovirus US28 facilitates cell-to-cell viral dissemination. Viruses 2014; 6(3).
Bongers G, Pacer ME, Geraldino TH, Chen L, He Z, Hashimoto D, Furtado GC, Ochando J, Kelley KA, Clemente JC, Merad M, van Bakel H, Lira SA. Interplay of host microbiota, genetic perturbations, and inflammation promotes local development of intestinal neoplasms in mice. The Journal of experimental medicine 2014 Mar; 211(3).
Furtado GC, Pacer ME, Bongers G, Bénézech C, He Z, Chen L, Berin MC, Kollias G, Caamaño JH, Lira SA. TNFα-dependent development of lymphoid tissue in the absence of RORγt⁺ lymphoid tissue inducer cells. Mucosal immunology 2014 May; 7(3).
Hammerich L, Bangen JM, Govaere O, Zimmermann HW, Gassler N, Huss S, Liedtke C, Prinz I, Lira SA, Luedde T, Roskams T, Trautwein C, Heymann F, Tacke F. Chemokine receptor CCR6-dependent accumulation of γδ T cells in injured liver restricts hepatic inflammation and fibrosis. Hepatology (Baltimore, Md.) 2014 Feb; 59(2).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Lira did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.